Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...

This article presents a comprehensive overview of the molecular mechanisms underlying the anti-cancer properties of ICA, and further highlights recent progress in use of ICA in cancer research, ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...